Status:
COMPLETED
Safety Study of Apixaban in Recent Acute Coronary Syndrome
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Acute Coronary Syndrome (ACS)
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
Eligibility Criteria
Inclusion
- Key
- Recent (\< = 7 days) Acute Coronary Syndrome (ACS).
- Clinically stable on optimal treatment
- Key
Exclusion
- High bleeding risk.
- Ongoing anticoagulant use.
- Need for chronic (\>3 months) daily nonsteroidal anti-inflammatory drug (NSAID) or chronic high dose acetylsalicylic acid (ASA) use (\>325 mg/day
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
1741 Patients enrolled
Trial Details
Trial ID
NCT00313300
Start Date
May 1 2006
End Date
May 1 2008
Last Update
December 30 2015
Active Locations (151)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale Cardiovasular Research Institute
Scottsdale, Arizona, United States, 85251
2
Los Angeles County & University Of Southern Ca. Medical Cen.
Los Angeles, California, United States, 90033
3
Radiant Research,Santa Rosa
Santa Rosa, California, United States, 95405
4
South Denver Cardiology Associates
Littleton, Colorado, United States, 80120